Fig. 3.

Intratumor MLKL-mRNA protects better than doxorubicin treatment. a Schematic representation of the experiment. B16 cells were inoculated s.c. in the right flank of C57BL/6J (n = 8 per group). On days 6 and 10, intratumor injection of PBS, Fluc mRNA, tBid mRNA, or MLKL-mRNA followed by electroporation was performed. Doxorubicin (dox, 3 mg/kg per injection) was administered i.p. or intratumorally every second day starting on day 6. One group of mice received 3 intratumor injections of dox on days 6, 8, and 10. b Tumor growth progression over time depicted for the individual mice in each group. The animals were euthanized when the tumor had reached a size of 1000 mm³. c Survival curves and d body weight changes of the treated mice. Data points indicate average body weight change relative to day 10 and the error bars depict the standard deviation. **p < 0.01, ***p < 0.001, ****p < 0.0001, ns non-significant determined by log-rank test of Kaplan–Meier survival curves and by one-way ANOVA for the body weight graphs. e Hematologic analyses of the number of lymphocytes in blood collected on days 11, 18, and 25 from the treated mice. Each bar represents the average of 8 mice and the error bars depict the standard deviation. The y axis depicts the number of lymphocytes per µl of blood